Agilisium Named Select Services Partner in the Claude Partner Network
Agilisium Named Select Services Partner in the Claude Partner Network
PR Newswire
LOS ANGELES, July 22, 2026
LOS ANGELES, July 22, 2026 /PRNewswire/ -- Agilisium – A Context-Centric AI company that combines FDX and Claude to deliver measurable outcomes for Life Sciences clients, today announced it has been named a Select Services Partner in the Claude Partner Network, Anthropic's global ecosystem for organizations building and delivering solutions on Claude.
This partner status reflects Agilisium's demonstrated track record of implementing Claude-powered agentic AI solutions for Life Sciences clients in production environments — including live deployments for its clients via Amazon Bedrock.
Through this partnership, Agilisium will combine its Context-Centric AI solutions and proprietary FDX (Forward Deployment Expert) framework with Claude's advanced reasoning ability to deliver measurable business impact for its Life Sciences clients.
Anthropic and Agilisium — A Purpose-Built Combination for Life Sciences
In March 2026, Agilisium announced a US$5.5 million investment to build and deploy its FDX model — embedding AI transformation experts directly inside Life Sciences client organizations across four dimensions: Domain, AI and Technology, Consultative Solutioning, and Systems and Process Thinking. As part of that initiative, Agilisium's FDX practitioners are now being trained and certified on Claude, powered by Anthropic, making it the AI platform of choice within the FDX delivery model for Life Sciences.
Domain tells AI what the industry is. Context tells AI how a specific enterprise actually operates. This distinction defines Agilisium's approach — and why FDX and Claude together are uniquely positioned to help pharma and biotech organizations move from AI ambition to enterprise-grade outcomes.
Agilisium is establishing the 'Agilisium Claude Life Sciences Center of Excellence', with Context-Centric Transformation Labs across Clinical Development, Regulatory Affairs, Medical Affairs, Pharmacovigilance, Commercial Operations, and Manufacturing.
"Life Sciences is a domain where the cost of getting AI wrong is measured not just in business outcomes, but in patients' well-being. Our FDX framework, combined with Claude's advanced reasoning capability, its contextual depth, and Anthropic's commitment to responsible AI, makes it the right foundation for the complex, high-stakes environments our clients operate in. This partnership status is a reflection of our team's commitment — and the beginning of a much deeper, outcome-centric collaboration."
— Raj Babu, CEO and Founder, Agilisium
"Our goal is to build one of the deepest Claude capabilities in the Life Sciences domain. We are investing in a long-term collaboration with Anthropic that goes well beyond partner status — one that will enable our clients to experience enterprise-grade AI that is validated for regulated environments and delivers innovation at scale."
— Arunkumar Arjunan, Chief Operating Officer and Chief AI and Innovation Officer, Agilisium
About Agilisium
Agilisium – The World's First Life Sciences Context-Centric AI Consulting & Services Company, from Molecule to Market. The company delivers cutting-edge solutions that drive impactful change by combining strong domain expertise with Contextual Autonomous Agentic AI and Advanced Analytics. Agilisium collaborates with leading pharma and biotech companies to provide hyper automation of mission-critical business processes, data-driven insights, and innovative solutions across the value chain, helping accelerate drug discovery, optimize patient care, achieve commercial success, streamline product delivery, and foster collaboration. The company's commitment to rigorous execution and continuous innovation enables it to shape the future of the Life Sciences industry.
For more information, visit www.agilisium.com
SOURCE Agilisium Consulting
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States